Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.41 |
| ▸ | GLS | O94925 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15700313 | 0.86 | HDAC1 (0.44) | HDAC1KDM4ATRPV1L3MBTL1NAMPT | |
| SCHEMBL13055397 | 0.86 | KDM4A (0.51) | HDAC1KDM4AL3MBTL1NAMPTGAA | |
| SCHEMBL4453472 | 0.84 | NQO2 (0.48) | NAMPTGAASERPINE1CA1CA2 | |
| SCHEMBL21063347 | 0.84 | KDM4A (0.45) | HDAC1KDM4AL3MBTL1NAMPTGAA | |
| SCHEMBL7540531 | 0.83 | GAA (0.47) | HDAC1KDM4AL3MBTL1NAMPTGAA | |
| SCHEMBL2959710 | 0.83 | HDAC1 (0.40) | HDAC1KDM4AL3MBTL1NAMPTGAA | |
| SCHEMBL21593060 | 0.83 | KDM4A (0.44) | HDAC1KDM4AL3MBTL1NAMPTGAA | |
| SCHEMBL8256927 | 0.83 | TSHR (0.50) | HDAC1KDM4ATRPV1L3MBTL1NAMPT | |
| SCHEMBL2005452 | 0.82 | TSHR (0.43) | HDAC1KDM4AL3MBTL1NAMPTGAA | |
| SCHEMBL2948641 | 0.82 | HDAC1 (0.42) | HDAC1KDM4AL3MBTL1NAMPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288077-A1 | SUBSTITUTED 4-PHENOXYPHENOL ANALOGS AS MODULATORS OF PROLIFERATING CELL NUCLEAR ANTIGEN ACTIVITY | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288077-A1 | SUBSTITUTED 4-PHENOXYPHENOL ANALOGS AS MODULATORS OF PROLIFERATING CELL NUCLEAR ANTIGEN ACTIVITY | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288077-A1 | SUBSTITUTED 4-PHENOXYPHENOL ANALOGS AS MODULATORS OF PROLIFERATING CELL NUCLEAR ANTIGEN ACTIVITY | MKI67, PCNA, PCLAF | HDAC1 321/4885KDM4A 195/4885TRPV1 4060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.